Five Rings Tech Reports Impressive 2022 Half-Year Results

Aug.17.2022
Five Rings Tech Reports Impressive 2022 Half-Year Results
Tech company Wulun Technology saw a 235.19% YoY increase in H1 2022 revenue, driven by sales of disposable e-cigarettes.

On August 16th, Wulun Technology (833767) recently released their 2022 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 359,397,617.56, a year-on-year increase of 235.19%; net profit attributable to the listed company's shareholders was RMB 59,764,282.62, a year-on-year increase of 474.03%.


During the reporting period, the net cash flow generated by operating activities was RMB 84,449,058.51, with a net asset of RMB 89,895,077.97 attributable to the listed company's shareholders.


During the reporting period, the company achieved a revenue of 359,397,617.56 yuan, an increase of 235.19% year-on-year. The main reason for this is that the company's disposable electronic cigarette product design met market demand, resulting in an increase in sales of both OEM and self-branded electronic cigarette products, with the fastest growth in sales occurring in Europe.


The operating costs increased by 233.45% compared to the same period last year, primarily due to a 235.19% increase in operating revenue, resulting in a year-on-year increase in costs.


The company's operating profit increased by 548.11% compared to the same period last year, primarily due to two reasons: Firstly, this year's operating revenue increased by 235.19%, or 252,175,395.00 yuan, to 359,397,617.56 yuan, compared to 107,222,222.56 yuan in the previous period. Secondly, the company's financial expenses decreased by 669.32%, or 7,093,496.55 yuan, to -6,033,682.72 yuan, compared to 1,059,813.83 yuan in the previous period. This increase in revenue and decrease in expenses led to an increase in operating profit.


According to data from Wabei.com, Five Rings Technology's main products and services revolve around research and development, production, and sales of electronic cigarettes and related accessories.


The contents excerpted or reproduced in this article are sourced from third-party information, and their copyrights belong to the original media and authors. If there is any infringement, please contact us to delete it. Any unit or individual wishing to reproduce it must contact the author and not directly reproduce it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
Vape Manufacturer Ispire Expands Malaysia Operations, Negotiates Southeast Asia OEM Deal as Nicotine Pouch and US Age-Gating Businesses Develop
US-listed vaping technology and manufacturing company Ispire Technology reported fiscal first-quarter 2027 revenue of $27.5 million on November 9, 2026, down 9.3% year over year but up 3.2% sequentially. Gross margin recovered to 16.2%, while its net loss widened to $6.4 million from $3.3 million a year earlier. Management attributed the sales decline primarily to tighter European vaping regulation and reduced distributor orders. Ispire is expanding manufacturing in Malaysia and negotiating an OEM/ODM agreement with a Southeast Asian vaping brand, with an announcement anticipated in January 2027. The company estimates that Malaysian manufacturing offers an approximately 25% US tariff advantage over China-based production. However, it continues to purchase products from Shenzhen Yi Jia Technology Co., Ltd., a manufacturer controlled by its chairman, and reported $52 million in non-current related-party payables at September 30.
company
Nov.11 by 2Firsts Perspectives
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
New Australian government estimates released on November 15, 2026, suggest that the country's illicit tobacco market may have contracted for the first time following five years of growth. Estimated market volume fell from a previous peak of 5,972 tonnes to a range of 4,453–5,893 tonnes. The government attributed the change to stronger border enforcement and coordinated domestic operations. Australian Border Force seized more than 2,300 tonnes of illicit tobacco and 13.2 million illicit vaping products in 2025–26, followed by approximately 730 tonnes of illicit tobacco in the first quarter of 2026–27. Separate experimental estimates from the Australian Bureau of Statistics indicate that illicit sources accounted for approximately 80% of nicotine consumption in 2025.
Regulations
Nov.16
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10